Applied Filters
Sanofi v Amgen antibody case lands front of queue at UPC
Big pharma company picks pan-European venue for next leg of global dispute | IT issues potentially behind new court's low revocation count | Nearly half a million opt-outs registered.
Effects of GSK v Teva ripple after SCOTUS denies cert
Despite one judge’s insistence that the case was “narrow and fact dependent”, GSK v Teva could have wide-reaching implications for generic drugs, biosimilars, and how skinny labels are read, say Chad Landmon, Ross Blau, Gulrukh Haroon of Axinn, Veltrop & Harkrider.
South Africa: Hope for measures to prevent abuse of the patent system
Government-led schemes to incentivise patents are leading to delays and prejudice against legitimate applicants. Tyron Grant of Spoor and Fisher explains how South Africa is tackling the problem.
Brazil: The patent combination conundrum
It may not be straightforward but it is possible to obtain protection for valuable combination patents in Brazil, say Lívia Figueiredo and Priscila Kashiwabara of Kasznar Leonardos Intellectual Property.
Amgen v Sanofi: Scotus grapples with enablement
As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Humira: lessons from 20 years of patents, pricing and profits
As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.
Pfizer’s pregabalin litigation: the latest twist
The long-running legal saga between the pharma giant and the NHS as well as generic drug makers has developed further, as Darren Smyth of EIP explains.
Japan: DOE and cross-border infringement of a biologics process patent
The Tokyo District Court judgment on patent infringement and question of territoriality is game-changing, says Takanori Abe of Abe & Partners.
Why Novartis lost its treatment dispute with Teva
The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.
Amgen v Sanofi: Big Pharma awaits SCOTUS decision
As patent attorneys look ahead to 2023's key rulings, Timothy Sendek of Akerman offers insights on the pending enablement case at the Supreme Court.
